The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for etirinotecan pegol intended for the treatment of advanced breast cancer with brain metastases. Consequently the first appraisal committee discussion of this topic, has been cancelled. We will continue to monitor any developments and will update interested parties if the situation changes.
 
Status Suspended
Process STA
ID number 881

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
25 July 2017 Suspended, The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for etirinotecan pegol intended for the treatment of advanced breast cancer with brain metastases. Consequently the first appraisal committee discussion of this topic, has been cancelled. We will continue to monitor any developments and will update interested parties if the situation changes.
18 August 2016 Invitation to participate
02 June 2016 Draft scope documents
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance